GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioVaxys Technology Corp (XCNQ:BIOV) » Definitions » ROIC %

BioVaxys Technology (XCNQ:BIOV) ROIC % : -229.62% (As of Jul. 2023)


View and export this data going back to 2018. Start your Free Trial

What is BioVaxys Technology ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. BioVaxys Technology's annualized return on invested capital (ROIC %) for the quarter that ended in Jul. 2023 was -229.62%.

As of today (2024-06-18), BioVaxys Technology's WACC % is 12.04%. BioVaxys Technology's ROIC % is -161.20% (calculated using TTM income statement data). BioVaxys Technology earns returns that do not match up to its cost of capital. It will destroy value as it grows.


BioVaxys Technology ROIC % Historical Data

The historical data trend for BioVaxys Technology's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioVaxys Technology ROIC % Chart

BioVaxys Technology Annual Data
Trend Oct18 Oct19 Oct20 Oct21 Oct22
ROIC %
- -289.33 -14.84 -85.74 -104.92

BioVaxys Technology Quarterly Data
Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -47.74 -95.15 -2,440.00 -383.35 -229.62

Competitive Comparison of BioVaxys Technology's ROIC %

For the Biotechnology subindustry, BioVaxys Technology's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioVaxys Technology's ROIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioVaxys Technology's ROIC % distribution charts can be found below:

* The bar in red indicates where BioVaxys Technology's ROIC % falls into.



BioVaxys Technology ROIC % Calculation

BioVaxys Technology's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Oct. 2022 is calculated as:

ROIC % (A: Oct. 2022 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Oct. 2021 ) + Invested Capital (A: Oct. 2022 ))/ count )
=-4.082 * ( 1 - 0% )/( (7.63 + 0.151)/ 2 )
=-4.082/3.8905
=-104.92 %

where

BioVaxys Technology's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Jul. 2023 is calculated as:

ROIC % (Q: Jul. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Apr. 2023 ) + Invested Capital (Q: Jul. 2023 ))/ count )
=-2.248 * ( 1 - 0% )/( (1.485 + 0.473)/ 2 )
=-2.248/0.979
=-229.62 %

where

Note: The Operating Income data used here is four times the quarterly (Jul. 2023) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioVaxys Technology  (XCNQ:BIOV) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, BioVaxys Technology's WACC % is 12.04%. BioVaxys Technology's ROIC % is -161.20% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


BioVaxys Technology ROIC % Related Terms

Thank you for viewing the detailed overview of BioVaxys Technology's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


BioVaxys Technology (XCNQ:BIOV) Business Description

Traded in Other Exchanges
Address
146 Thirtieth Street, Suite 100, Etobicoke, ON, CAN, M8W 3D4
BioVaxys Technology Corp is a clinical-stage biopharma company. The company develops antiviral and anticancer vaccine platforms to treat SARS-CoV-2 and other viral infections, as well as ovarian cancer and other solid tumor types.
Executives
James Passin Director, Senior Officer

BioVaxys Technology (XCNQ:BIOV) Headlines

No Headlines